Assessment of electrolyte imbalance among benign prostate hyperplasia patients in Western Kenya


  • Royronald Ongonga Department of Medical Laboratory Science, Kenyatta University, Nairobi, Kenya
  • Nelson Menza Department of Medical Laboratory Science, Kenyatta University, Nairobi, Kenya
  • Rodgers N. Demba Department of Medical Laboratory Science, Maseno University, Nyanza, Kenya



Benign prostate hyperplasia, Imbalance, Kidneys, PSA, Serum electrolyte


Background: Benign prostate hyperplasia (BPH) results in the enlargement of the gland and ultimately obstructs the bladder and the kidney. The effect on the kidney results in the dysregulation of the electrolyte causing electrolyte imbalance.

Methods: An analytical cross-sectional study conducted at a tertiary teaching hospital aimed at assessing the levels and severity of electrolyte imbalance among BPH patients. The blood samples were analyzed for electrolytes and PSA levels for both patients and control group. An Independent t-test was used to compare the means of the BPH patients and healthy control subjects. Chi-square was used to determine the association between the electrolyte imbalance and the PSA levels of the BPH patients.

Results: The mean age of the BPH patients and the healthy individuals was 65.47±12.55 and 64.52±12.19 years respectively. Hyponatremia, and hypernatremia were observed in 26.08% (n=104) and 4.22% (n=8) of the BPH patients respectively. There was a statistical significance positive correlation between potassium (K) and sodium (Na) concentrations (r=0.350, p<0.01), as well as a notable positive association between chloride (Cl) and magnesium (Mg) levels (r=0.288, p<0.01). PSA biomarker levels varied among the patients. There was a statistical significance (<0.0001*) difference in PSA levels between the BPH patients and the control group.

Conclusions: With high prevalence of electrolyte imbalance among BPH patients there is a need to monitor the electrolytes and PSA levels in the management of BPH aiming at restoration of kidney function.


Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian journal of urology: IJU: J Urolog Soci India. 2014;30(2):170.

Langan RC. Benign prostatic hyperplasia. Primary Care: Clin Off Pract. 2019;46(2):223-32.

Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127(6):722-8.

Xu XF, Liu GX, Guo YS, Zhu HY, He DL, Qiao XM, et al. Global, regional, and national incidence and year lived with disability for benign prostatic hyperplasia from 1990 to 2019. Am J Men's Heal. 2021;15(4):15579883211036786.

Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Heal Long. 2022;3(11):e754-76.

Ngugi AK, Agoi F, Mahoney MR, Lakhani A, Mang’ong’o D, Nderitu E, et al. Utilization of health services in a resource-limited rural area in Kenya: prevalence and associated household-level factors. PloS one. 2017;12(2):e0172728.

Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014:1-14.

Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal Jr DE, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8(5):529.

Roehrborn CG. Benign prostatic hyperplasia: an overview. Revi Urol. 2005;7(Suppl 9):S3.

De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nature Revi Urol. 2016;13(10):613-26.

Shrimanker I, Bhattarai S. Electrolytes. In: StatPearls Publishing, Treasure Island (FL); 2019.

Porth C, Porth C. Essentials of pathophysiology: concepts of altered health states. Wolters Kluwer/Lippincott Williams & Wilkins; 2011.

Laville M, Burst V, Peri A, Verbalis JG. Hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): therapeutic decision-making in real-life cases. Clin Kid J. 2013;6(suppl_1):i1-20.

Berardi R, Torniai M, Lenci E, Pecci F, Morgese F, Rinaldi S. Electrolyte disorders in cancer patients: a systematic review. J Can Meta Treat. 2019;5(79):1-33.

Timerga A, Kelta E, Kenenisa C, Zawdie B, Habte A, Haile K. Serum electrolytes disorder and its associated factors among adults admitted with metabolic syndrome in Jimma Medical Center, South West Ethiopia: Facility based crossectional study. PloS one. 2020;15(11):e0241486.

Altaf J, Arain AH, Devrajani BR, Baloch S. Serum electrolyte disturbances in benign prostate hyperplasia after transurethral resection of the prostate. J Nephrol Ther. 2016;6(238):2161-0959.

Pourfridoni M, Abbasnia SM, Shafaei F, Razaviyan J, Heidari-Soureshjani R. Fluid and electrolyte disturbances in COVID-19 and their complications. BioMed Res Int. 2021;2021:1-5.

Asare GA, Ngala RA, Afriyie D, Adjei S, Nyarko A, Anang-Quartey Y, et al. Calcium-Magnesium imbalance implicated in benign prostatic hyperplasia and restoration by a phytotherapeutic drug–Croton membranaceus Müll. Arg. BMC complem Alter Medi. 2017;17(1):1-8.

Liu M, Yang H, Mao Y. Magnesium and liver disease. Ann Translat Medi. 2019;7(20):578.

Iqbal S, Raiz I, Faiz I. Bilateral hydroureteronephrosis with a hypertrophied, trabeculated urinary bladder. MJMS. 2017;24(2):106.

Puckett L. Renal and electrolyte complications in eating disorders: a comprehensive review. J Eat Dis. 2023;11(1):26.

Kee YK, Jeon HJ, Oh J, Shin DH. Dyschloremia is associated with failure to restore renal function in survivors with acute kidney injury: an observation retrospective study. Sci Rep. 2020;10(1):19623.

Ding X, Cheng Z, Qian Q. Intravenous fluids and acute kidney injury. Blood Puri. 2017;43(1-3):163-72.

Narins RG, Maxwell & Kleeman’s Clinical disorders of fluid and electrolyte metabolism. 5th ed. McGraw-Hill, Health Professions Division; 1994.

Brinkman JE, Sharma S. Physiology, Metabolic Alkalosis. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2023.

Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontol. 2019;65(5):458-64.

Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20(3):S11-8.

Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383-91.

Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2):407-13.

Cakir SS, Polat EC, Ozcan L, Besiroglu H, Ötunctemur A, Ozbek E. The effect of prostatic inflammation on clinical outcomes in patients with benign prostate hyperplasia. Prostate Int. 2018;6(2):71-4.




How to Cite

Ongonga, R., Menza, N., & Demba, R. N. (2023). Assessment of electrolyte imbalance among benign prostate hyperplasia patients in Western Kenya. International Journal of Research in Medical Sciences, 12(1), 37–43.



Original Research Articles